Panoptes Pharma Ges.m.b.H., a new biopharmaceutical company founded in Vienna, Austria, has announced the successful closing of its seed funding investment round of EUR1.2M. The company, founded by Dr. Franz Obermayr and Dr. Stefan Sperl, is planning to develop a lead clinical candidate, “PP-001”, for the treatment of autoimmune uveitis, a chronic inflammatory disease which can lead to blindness. The investment round was funded by private investors and aws Life Science Austria (LISA). LISA, a promoter of the life sciences sector in Austria, is run by Austria Wirtschaftsservice GesmbH (aws) on behalf of the Austrian Federal Ministry of Economy, Family and Youth.
Panoptes Pharma raises first investment for novel chronic uveitis treatment
- by swdadmin